Medivation to Host Conference Call at 8:30 a.m. Eastern Time Tomorrow to Discuss Phase 3 Trial Results for Dimebon in Alzheimer's Disease

SAN FRANCISCO, March 2 /PRNewswire-FirstCall/ -- Medivation, Inc. (Nasdaq: MDVN) today announced that it will hold a teleconference and webcast at 8:30 a.m. Eastern Time tomorrow, Wednesday, March 3, to discuss Phase 3 trial results for dimebon (latrepirdine) in patients with mild-to-moderate Alzheimer's Disease.  A press release will be issued at 7:30 a.m. Eastern Time tomorrow prior to this call.

Teleconference/Webcast Details

To participate in the live call on Wednesday, March 3, at 8:30 a.m. Eastern Time (5:30 a.m. Pacific Time), please dial 877-303-2523 for domestic callers and 1-253-237-1755 for international callers. In addition, the live conference call is being webcast and can be accessed on the "Events and Presentations" page of the "Investor Relations" section of the Company's website at www.medivation.com. A replay also will be available for 30 days following the live call.

About Medivation

Medivation, Inc. is a biopharmaceutical company focused on the rapid development of novel small molecule drugs to treat serious diseases for which there are limited treatment options. Medivation aims to transform the treatment of these diseases and offer hope to critically ill patients and their caregivers. In September 2008, Medivation announced a global agreement with Pfizer, Inc to develop and commercialize dimebon (latrepirdine) for the treatment of Alzheimer's and Huntington diseases. With Pfizer, Medivation is conducting a broad dimebon clinical development program that includes several Phase 3 trials assessing the efficacy and safety of dimebon taken alone or in combination with other Alzheimer's medications in patients with mild, moderate and severe Alzheimer's disease. The companies are also conducting a Phase 3 trial of dimebon in Huntington disease. In October 2009, Medivation entered a global agreement with Astellas Pharma Inc. to develop and commercialize MDV3100 for both early- and late-stage prostate cancer. The first Phase 3 clinical trial in the MDV3100 development program, known as the AFFIRM trial, is under way in patients with castration-resistant prostate cancer who have previously been treated with docetaxel-based chemotherapy. For more information, please visit us at www.medivation.com.

SOURCE Medivation, Inc.